GeneDx Holdings (WGS) Change in Receivables (2020 - 2026)

GeneDx Holdings has disclosed Change in Receivables across 7 years of filings, most recently posting $2.6 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 70.11% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $30.2 million (up 68.36% YoY), while the FY2025 annual figure was $36.2 million, up 599.44% from the prior year.
• Change in Receivables declined to $2.6 million in Q1 2026, from $13.4 million in the prior quarter.
• Over the last five years, Change in Receivables for WGS reached as high as $13.4 million in Q4 2025 and fell as low as -$13.5 million in Q2 2022.
• The 5-year median for Change in Receivables is -$36000.0 (2022), against an average of $1.6 million.
• The widest YoY moves for Change in Receivables: up 2359.42% in 2024, down 435.0% in 2024.
• A 5-year view of Change in Receivables shows it stood at -$36000.0 in 2022, then soared by 655.56% to $200000.0 in 2023, then tumbled by 435.0% to -$670000.0 in 2024, then soared by 2104.78% to $13.4 million in 2025, then sank by 80.96% to $2.6 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $2.6 million, $13.4 million, and $12.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.